Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic and Microbiome Diversity Effects
2019-002476-14Phase 4Active
- Sponsor
- Oslo University Hospital
- Start
- Jul 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of mycophenolate and tacrolimus in kidney transplant, Kidney allograft status (RTx) and graft rejection, sponsored by Oslo University Hospital. Started Jul 2019; status: active.
02
Drugs
mycophenolatetacrolimus
03
Conditions
kidney transplantKidney allograft status (RTx)graft rejection
Beyond the preview
Go deeper on 2019-002476-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002476-14.